Latest Breaking News On - Intarcia therapeutics - Page 1 : comparemela.com

SeaStar Medical Appoints David A Green as Chief Financial Officer

SeaStar Medical Appoints David A Green as Chief Financial Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkUniversity of rochesterAytu biopharmaProlacta bioscienceEric schlorffCaryl baronJody cainDuff phelpsErnst young palo alto centerSeastar medical holding corporation nasdaqUniversity of new yorkSpecialized health products internationalStar medical holding corporationChief financial officerSeastar medical

C4 Therapeutics Inc (CCCC) Appoints Owen Hughes to its Board

C4 Therapeutics Inc (CCCC) Appoints Owen Hughes to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rowen hughesBruce downeyRadius healthTherapeutics incDartmouth collegeFidelity investmentsCullinan oncologyIntarcia therapeuticsWall streetBrookside capitalBain capitalPyramis advisorsSail bioGurnet point capitalTranslate bio

FDA committee unanimously rejects GLP-1 implant for type 2 diabetes

FDA committee unanimously rejects GLP-1 implant for type 2 diabetes
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Patrickh nachmanRobert greevyBydureon byettaConnieb newmanJill rolletUniversity of minnesotaYork university school of medicineVanderbilt universityEndocrinologic metabolic drugs advisory committeeMetabolic drugs advisory committeeMetabolic drugs advisoryIntarcia therapeuticsNew york university school

FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D

An implanted device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes received a unanimous no vote from an FDA advisory panel based on safety and other concerns.

United statesErica brittainUniversity of colorado hospitalMetabolic drugs advisory committeeGlucose management teamDrug administrationIntarcia therapeuticsBiostatistics research branchNational instituteInfectious diseasesMetabolic drugs advisoryFlow wangDiabetes mellitus type 2Iabetes mellitus type iiType 2 diabetesGlp 1 receptor agonists

FDA advisers discuss twice-rejected diabetes drug implant

FDA panel is gathering Sept. 21 to discuss ITCA 650, a Type 2 diabetes drug delivery product under review for possible approval. The experimental therapy has been denied approval twice.

United statesMetabolic drugs advisory committeeIntarcia therapeuticsTca 650Type 2 diabetesDrug deliveryIntarcia therapeuticsGlp 1